Embodiments of the subject matter described herein relate generally to fluid infusion devices, such as insulin pumps and insulin injection ports. More particularly, embodiments of the subject matter relate to an infusion set component having a physically distinct and modular fluid channel element.
Portable medical devices are useful for patients that have conditions that must be monitored on a continuous or frequent basis. For example, diabetics are usually required to modify and monitor their daily lifestyle to keep their blood glucose (BG) in balance. Individuals with Type 1 diabetes and some individuals with Type 2 diabetes use insulin to control their BG levels. To do so, diabetics routinely keep strict schedules, including ingesting timely nutritious meals, partaking in exercise, monitoring BG levels daily, and adjusting and administering insulin dosages accordingly.
The prior art includes a number of fluid infusion devices and insulin pump systems that are designed to deliver accurate and measured doses of insulin via infusion sets (an infusion set delivers the insulin through a small diameter tube that terminates at, e.g., a cannula inserted under the patient's skin). In lieu of a syringe, the patient can simply activate the insulin pump to administer an insulin bolus as needed, for example, in response to the patient's high BG level.
A typical infusion pump includes a housing, which encloses a pump drive system, a fluid containment assembly, an electronics system, and a power supply. The pump drive system typically includes a small motor (DC, stepper, solenoid, or other varieties) and drive train components such as gears, screws, and levers that convert rotational motor motion to a translational displacement of a stopper in a reservoir. The fluid containment assembly typically includes the reservoir with the stopper, tubing, and a catheter or infusion set to create a fluid path for carrying medication from the reservoir to the body of a user. The electronics system regulates power from the power supply to the motor. The electronics system may include programmable controls to operate the motor continuously or at periodic intervals to obtain a closely controlled and accurate delivery of the medication over an extended period.
The prior art also includes a variety of physiological characteristic (or analyte) sensors that are designed to measure an analyte of a patient. For example, continuous glucose sensors employ a subcutaneous glucose sensor technology that facilitates ongoing monitoring of blood glucose levels. Continuous glucose sensors may utilize wireless data communication techniques to transmit data indicative of the blood glucose levels to a portable infusion pump, a glucose monitor device, and/or other receiving devices. Thus, in a typical insulin pump system, the patient might wear both an infusion set (for the delivery of insulin) and a glucose sensor-transmitter.
The following description presents an exemplary embodiment of an infusion set component for a fluid infusion device that delivers fluid to a patient. The infusion set component includes a base and a fluid channel module coupled to the base. The base includes an attachment feature to accommodate removable coupling with a fluid tubing connector of the fluid infusion device, and a cavity formed therein to receive and maintain the fluid channel module. The fluid channel module includes an interior fluid flow channel to receive fluid from the fluid tubing connector. The fluid channel module also includes a conduit in fluid communication with the interior fluid flow channel to deliver fluid from the interior fluid flow channel. The interior fluid flow channel and the conduit cooperate to form a fluid flow path.
Also provided is an exemplary embodiment of a fluid channel module for an infusion set component of a fluid infusion device that delivers a fluid to a patient. The fluid channel module includes a body section having coupling features to mate with a base of the infusion set component. The fluid channel module also includes an interior fluid flow channel formed within the body section to receive the fluid from the fluid infusion device, and a conduit having a first end in fluid communication with the interior fluid flow channel, and having a second end to deliver the fluid to the patient.
Also provided is an exemplary embodiment of an infusion set component for a fluid infusion device that delivers a fluid to a patient using either a first fluid channel module or a second fluid channel module. The infusion set component includes a base body section, a fluid channel module interface formed in the base body section, and a sensor interface formed in the base body section. The fluid channel module interface has first universal coupling features that mate with corresponding second universal coupling features of the first fluid channel module and with corresponding third universal coupling features of the second fluid channel module. The sensor interface accommodates a sensor to facilitate sensing of an analyte of the patient.
An exemplary embodiment of a fluid infusion port component to accommodate delivery of fluid to a patient is also provided. The fluid infusion port component includes a base and a fluid channel module coupled to the base. The base has first universal coupling features that mate with corresponding second universal coupling features of the fluid channel module. The fluid channel module has an interior fluid flow channel having an inlet, along with a septum positioned at the inlet. The septum is pierced by a fluid delivery needle to accommodate delivery of fluid into the interior fluid flow channel. The septum seals the inlet when the fluid delivery needle is removed from the septum. The fluid channel module also includes a conduit in fluid communication with the interior fluid flow channel to deliver fluid from the interior fluid flow channel. The interior fluid flow channel and the conduit cooperate to form a fluid flow path.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
A more complete understanding of the subject matter may be derived by referring to the detailed description and claims when considered in conjunction with the following figures, wherein like reference numbers refer to similar elements throughout the figures.
The following detailed description is merely illustrative in nature and is not intended to limit the embodiments of the subject matter or the application and uses of such embodiments. As used herein, the word “exemplary” means “serving as an example, instance, or illustration.” Any implementation described herein as exemplary is not necessarily to be construed as preferred or advantageous over other implementations. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.
The subject matter described here relates to a fluid infusion device of the type used to treat a medical condition of a patient. The infusion device is used for infusing fluid into the body of a user. The non-limiting examples described below relate to a medical device used to treat diabetes (for example, an insulin pump, an injection port, or other type of insulin delivery system), although embodiments of the disclosed subject matter are not so limited. Accordingly, the infused fluid is insulin in certain embodiments. In alternative embodiments, however, many other fluids may be administered through infusion such as, but not limited to, disease treatments, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, medications, vitamins, hormones, or the like.
For the sake of brevity, conventional features and technologies related to infusion system operation, insulin pump and/or infusion set operation, blood glucose sensing and monitoring, sensor signal processing, and other functional aspects of the fluid infusion system (and the individual operating components of the system) may not be described in detail here. Examples of infusion pumps used to administer insulin and other medications may be of the type described in, but not limited to, U.S. Pat. Nos. 6,485,465; 6,554,798; 6,558,351; 6,752,787; 6,932,584; and 7,621,893; which are herein incorporated by reference.
In accordance with certain exemplary embodiments described herein, a fluid infusion system utilizes a combined infusion-sensor unit that functions to: (1) deliver a medication fluid to the body of a patient; and (2) sense or detect a measurable analyte or physiological characteristic of the patient. The combined infusion-sensor unit may be configured as an infusion set component that is compatible with a tubing component that provides the medication fluid from a fluid infusion device to the infusion set component. The infusion set component may also be compatible with a sensor transmitter component that transmits sensor data to a device within the fluid infusion system, e.g., the fluid infusion device or a monitor device.
The infusion set component is designed to accommodate a fluid channel module, which is manufactured as a physically distinct and separate component having a self-contained fluid path defined therein. The fluid channel module is installed into a base component to form the infusion set component. In certain embodiments, the base component includes a universal interface feature that receives and secures the fluid channel module. The interface feature is “universal” in that it is shaped, sized, and otherwise configured for compatibility with a plurality of different fluid channel module types. Thus, the infusion set component can be offered in different configurations in a cost efficient manner by using the same base component and installing the desired fluid channel module type. For example, one fluid channel module type could employ a soft cannula for the fluid delivery conduit, and another fluid channel module type could employ a stiff metal needle for the fluid delivery conduit. As another example, fluid channel modules having different needle dimensions (e.g., lengths) could be offered.
As mentioned above, the fluid channel module defines the fluid flow path for the infusion set component. Thus, the fluid channel module can be tested by itself to check the integrity of the fluid flow path. If the integrity of the flow path does not satisfy the required performance specifications, then the fluid channel module can be scrapped without having to sacrifice the entire infusion set component. Consequently, the use of a physically distinct and separate fluid channel module can reduce manufacturing cost.
Referring now to the drawings,
Although not always required, the exemplary embodiment of the infusion set component 104 is implemented as a combined infusion-sensor unit having a fluid infusion conduit for delivery of fluid from the fluid infusion device 102, and having an analyte sensor to sense or detect an analyte or physiological characteristic of the patient (such as blood glucose). In certain embodiments, the infusion set component 104 cooperates with a wireless sensor transmitter 116 such that data indicative of the measured analyte levels can be wirelessly transmitted to a compatible device, such as the fluid infusion device 102, a monitor device (not shown), a computing device (not shown), or the like.
The fluid infusion device 102 is designed to be carried or worn by the patient, and the tubing connector component 106 terminates at the infusion set component 104 such that the fluid infusion device 102 can deliver fluid to the body of the patient via the tube 108. The fluid infusion device 102 may leverage a number of conventional features, components, elements, and characteristics of existing fluid infusion devices. For example, the fluid infusion device 102 may incorporate some of the features, components, elements, and/or characteristics described in U.S. Pat. Nos. 6,485,465 and 7,621,893, the relevant content of which is incorporated by reference herein.
The fluid infusion device 102 accommodates the fluid reservoir 114 for the fluid that is delivered to the user. The tube 108 represents the fluid flow path that couples the fluid reservoir 114 to the infusion set component 104. When installed as depicted in
In certain embodiments, the infusion set component 200 includes a base and a fluid channel module coupled to the base. The fluid channel module can be manufactured as a separate component that becomes inseparable from the base after assembly. Notably, the fluid channel module is designed to completely define the fluid flow path for the infusion set component 200.
The base body section 300 includes features that accommodate the sensor 218 and the wireless sensor transmitter 210 (see
The base body section 300 also includes one or more attachment features that accommodate removable coupling with the fluid tubing connector 204 (see
The base body section 300 also includes a fluid channel module interface 330 formed therein. In certain embodiments, the fluid channel module interface 330 is integrally formed in the base body section 300 (e.g., by machining, molding, or the like). As shown in
For the illustrated embodiment of the base body section 300, the universal coupling features include, without limitation: two rails 332; a hole 334; and a lock tab 336 or other locking mechanism. These coupling features may be dimensioned with somewhat tight tolerances such that no adhesive or glue is needed to maintain the module in place. That said, adhesive, glue, bonding, or welding techniques could be utilized to reinforce this coupling. Notably, the distance between the two rails 332, the height of the two rails 332, the location, shape, and size of the hole 334, the location, shape, and size of the lock tab 336, the fore-aft dimensions of the two rails 332, and possibly other dimensions and characteristics of the fluid channel module interface 330 are defined for standardization with the different available fluid channel modules. Thus, although the internal construction and/or the particular specifications of the fluid conduits may vary from one fluid channel module to another, certain dimensions and features of all fluid channel modules will be compatible with the corresponding dimensions and features of the base body section 300. The function of these universal coupling features are described in more detail below.
The body section 402 may be realized as a unitary, one-piece component fabricated from a suitable material such as plastic, nylon, or the like. In certain embodiments, the body section 402 is a single-piece molded component. The body section 402 includes one or more coupling features that are suitably configured to mate with and couple to the universal coupling features of the base body section 300. For example, the body section 402 may include or cooperate with a snap hook 412 that engages the lock tab 336 of the base body section 300 (see
The body section 402 may also include an outlet port 416 that extends to accommodate the needle assembly 404. For this particular embodiment, the outer surface of the port 416 is cylindrical in shape, although other shapes and contours could be utilized. Notably, the hole 334 formed within the base body section 300 is universally shaped and sized to mate with the port 416. Referring again to
Referring to
Referring back to
The needle 434 represents one suitable implementation of a fluid delivery conduit for the infusion set component 200. The inlet end 438 of the needle 434 is in fluid communication with the interior fluid flow channel 420, and the needle 434 cooperates with the interior fluid flow channel 420 to form a self-contained and defined fluid flow path to the patient. When the fluid channel module 400 is secured in the base body section 300, the needle 434 passes through and extends from the hole 334. Thus, the needle 434 protrudes from the bottom of the infusion set component 200, as shown in
Referring again to
The fluid channel module 460 utilizes a different needle configuration than the fluid channel module 400. More specifically, the fluid channel module 460 includes a rigid needle 462 that is glued into the body section 464 (in contrast, the fluid channel module 400 employs the needle assembly 404, which may be attached via a snap fit, a press fit, or any suitable physical interconnection). For ease of understanding,
As mentioned previously, the fluid channel modules 400, 460 are compatible with the universal coupling and attachment features of the base body section 300. Thus, the fluid channel module interface 330 of the base body section 300 can receive and maintain the fluid channel modules 400, 460 to form a needle-based combined infusion-sensor unit if so desired to suit the needs of the patient. Alternatively, a different type of fluid channel module could be installed if needed. In this regard,
The external dimensions, features, and configuration of the body section 502 are similar (if not identical) to those found in the body section 402 of the fluid channel module 400. Indeed, the external dimensions, shape, and structure of the body section 502 are compatible with the universal coupling design of the infusion set component 200, as described above. Accordingly, the body section 502 includes an integrated snap hook 516, a retaining lip 518, and an output port 520 that facilitate coupling and attachment of the fluid channel module 500 into the base body section 300.
The outlet port 520 has a funnel-shaped internal opening 522 (see
Referring to
The needle funnel 506 is located within the interior fluid flow channel 530, and it may serve as a retaining element for the pliable cannula 504. In this regard, the end portion 524 of the pliable cannula 504 receives the base section 526 of the needle funnel 506. This arrangement is desirable to hold and position the end portion 524 between the base section 526 of the needle funnel 506 and the funnel-shaped internal opening 522 (see
The cannula 504 represents one suitable implementation of a fluid delivery conduit for the fluid channel module 500. The free end 540 of the cannula 504 represents the subcutaneous portion of the cannula 504 that serves to deliver the fluid to the patient. In contrast, the end portion 524 of the cannula 504 is located within the interior fluid flow channel 530. When the fluid channel module 500 is secured in the base body section 300, the cannula 504 passes through and extends from the hole 334. Thus, the cannula 504 protrudes from the bottom of the infusion set component 200, as shown in
The septum 512 and the septum cap 514 are similar to their equivalents described above for the fluid channel module 400. The illustrated embodiment of the fluid channel module 500 also employs the additional septum 508 and the additional septum cap 510. The septum 508 is located and held in place in the body section 502 by the septum cap 510. The septum 508 applies downward pressure on the needle funnel 506 to retain the needle funnel 506 in place and to form a seal around the cannula 504. The septum 508 has a nominal non-pierced state where the septum 508 seals an introducer inlet 544 of the interior fluid flow channel 530. The non-pierced state of the septum 508 is shown in
Referring to
As mentioned previously, the fluid channel module 500 is compatible with the universal coupling and attachment features of the base body section 300. Thus, the fluid channel module interface 330 of the base body section 300 can receive and maintain the fluid channel module 500 to form a cannula-based combined infusion-sensor unit if so desired to suit the needs of the patient. It should be appreciated that more than two different fluid channel module designs could be fabricated for compatibility with the base body section 300. The universal coupling features of the fluid channel module interface 330 allow a manufacturer to efficiently and effectively offer a variety of different infusion set configurations as needed to satisfy the needs of different patients, physicians, medical device providers, and caregivers.
Each of the fluid channel modules described above represents a side-entry component in that the needle of the fluid tubing connector enters the fluid channel module from the side (see, for example,
In contrast to the side-entry fluid channel modules, the fluid channel module 602 includes a vertically oriented fluid flow channel that leads to a fluid delivery cannula 606 (or, in alternative embodiments, a rigid needle). Accordingly, the fluid channel module 602 and the base body section 604 need not include any side ports or inlets. The fluid channel module 602 shares some features and elements with the fluid channel module 500. For the sake of brevity, common features, characteristics, and functional aspects will not be redundantly described here in the context of the fluid channel module 602.
The fluid infusion system 600 may also include a fluid tubing connector 610 (only a portion of which is depicted in
Each of the fluid channel modules described above cooperate with a fluid infusion device and an associated fluid tubing connector that physically and fluidly couples the fluid channel module to the fluid infusion device. As mentioned above with reference to
The fluid infusion port system 700 generally includes, without limitation: a base 706 and a fluid channel module 708 coupled to the base 706. The fluid channel module 708 shares many features and characteristics with the fluid channel modules 400, 500, 602 described above. For the sake of brevity, common features, characteristics, and functional aspects will not be redundantly described here in the context of the fluid channel module 708.
The fluid infusion port system 700 is designed to be worn by the patient with a conduit 710 (e.g., a cannula as shown) inserted subcutaneously. When a bolus or dose of medication fluid is needed, the patient inserts the syringe needle 704 into the fluid channel module 708, and actuates the plunger of the syringe 702 to force the desired amount of fluid into the body via the conduit 710. More specifically, the syringe needle 704 (or any suitable fluid delivery needle) is inserted by piercing the septum 712, which normally covers and seals the inlet of the interior fluid flow channel defined within the fluid channel module 708. In practice, the syringe needle 704 is forced through the septum 712 and into the interior fluid flow channel such that fluid from the syringe 702 can be delivered to the interior fluid flow channel. The interior fluid flow channel and the conduit 710 cooperate to define and form a fluid flow path of the fluid infusion port system 700. When the syringe needle 704 is refracted and removed from the septum 712, the septum heals itself to seal the inlet.
It should be appreciated that various features and aspects of the other fluid channel modules described herein may also be incorporated for use with the fluid channel module 708 and the fluid infusion port system 700 if so desired. For example, the base 706 could be suitably configured to accommodate a sensor to sense an analyte of the patient (as described above with reference to
While at least one exemplary embodiment has been presented in the foregoing detailed description, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or embodiments described herein are not intended to limit the scope, applicability, or configuration of the claimed subject matter in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing the described embodiment or embodiments. It should be understood that various changes can be made in the function and arrangement of elements without departing from the scope defined by the claims, which includes known equivalents and foreseeable equivalents at the time of filing this patent application.
This application claims the benefit of U.S. provisional patent application Ser. No. 61/586,647, filed Jan. 13, 2012 (the content of which is incorporated by reference herein).
Number | Name | Date | Kind |
---|---|---|---|
3631847 | Hobbs, II | Jan 1972 | A |
4212738 | Henne | Jul 1980 | A |
4270532 | Franetzki et al. | Jun 1981 | A |
4282872 | Franetzki et al. | Aug 1981 | A |
4373527 | Fischell | Feb 1983 | A |
4395259 | Prestele et al. | Jul 1983 | A |
4433072 | Pusineri et al. | Feb 1984 | A |
4443218 | DeCant, Jr. et al. | Apr 1984 | A |
4494950 | Fischell | Jan 1985 | A |
4542532 | McQuilkin | Sep 1985 | A |
4550731 | Batina et al. | Nov 1985 | A |
4559037 | Franetzki et al. | Dec 1985 | A |
4562751 | Nason et al. | Jan 1986 | A |
4671288 | Gough | Jun 1987 | A |
4678408 | Nason et al. | Jul 1987 | A |
4685903 | Cable et al. | Aug 1987 | A |
4731051 | Fischell | Mar 1988 | A |
4731726 | Allen, III | Mar 1988 | A |
4781798 | Gough | Nov 1988 | A |
4803625 | Fu et al. | Feb 1989 | A |
4809697 | Causey, III et al. | Mar 1989 | A |
4826810 | Aoki | May 1989 | A |
4871351 | Feingold | Oct 1989 | A |
4898578 | Rubalcaba, Jr. | Feb 1990 | A |
5003298 | Havel | Mar 1991 | A |
5011468 | Lundquist et al. | Apr 1991 | A |
5019974 | Beckers | May 1991 | A |
5050612 | Matsumura | Sep 1991 | A |
5078683 | Sancoff et al. | Jan 1992 | A |
5080653 | Voss et al. | Jan 1992 | A |
5097122 | Colman et al. | Mar 1992 | A |
5100380 | Epstein et al. | Mar 1992 | A |
5101814 | Palti | Apr 1992 | A |
5108819 | Heller et al. | Apr 1992 | A |
5153827 | Coutre et al. | Oct 1992 | A |
5165407 | Wilson et al. | Nov 1992 | A |
5247434 | Peterson et al. | Sep 1993 | A |
5262035 | Gregg et al. | Nov 1993 | A |
5262305 | Heller et al. | Nov 1993 | A |
5264104 | Gregg et al. | Nov 1993 | A |
5264105 | Gregg et al. | Nov 1993 | A |
5284140 | Allen et al. | Feb 1994 | A |
5299571 | Mastrototaro | Apr 1994 | A |
5307263 | Brown | Apr 1994 | A |
5317506 | Coutre et al. | May 1994 | A |
5320725 | Gregg et al. | Jun 1994 | A |
5322063 | Allen et al. | Jun 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5339821 | Fujimoto | Aug 1994 | A |
5341291 | Roizen et al. | Aug 1994 | A |
5350411 | Ryan et al. | Sep 1994 | A |
5356786 | Heller et al. | Oct 1994 | A |
5357427 | Langen et al. | Oct 1994 | A |
5368562 | Blomquist et al. | Nov 1994 | A |
5370622 | Livingston et al. | Dec 1994 | A |
5371687 | Holmes, II et al. | Dec 1994 | A |
5376070 | Purvis et al. | Dec 1994 | A |
5390671 | Lord et al. | Feb 1995 | A |
5391250 | Cheney, II et al. | Feb 1995 | A |
5403700 | Heller et al. | Apr 1995 | A |
5411647 | Johnson et al. | May 1995 | A |
5482473 | Lord et al. | Jan 1996 | A |
5485408 | Blomquist | Jan 1996 | A |
5497772 | Schulman et al. | Mar 1996 | A |
5505709 | Funderburk et al. | Apr 1996 | A |
5543326 | Heller et al. | Aug 1996 | A |
5569186 | Lord et al. | Oct 1996 | A |
5569187 | Kaiser | Oct 1996 | A |
5573506 | Vasko | Nov 1996 | A |
5582593 | Hultman | Dec 1996 | A |
5586553 | Halili et al. | Dec 1996 | A |
5593390 | Castellano et al. | Jan 1997 | A |
5593852 | Heller et al. | Jan 1997 | A |
5594638 | Iliff | Jan 1997 | A |
5609060 | Dent | Mar 1997 | A |
5626144 | Tacklind et al. | May 1997 | A |
5630710 | Tune et al. | May 1997 | A |
5643212 | Coutre et al. | Jul 1997 | A |
5660163 | Schulman et al. | Aug 1997 | A |
5660176 | Iliff | Aug 1997 | A |
5665065 | Colman et al. | Sep 1997 | A |
5665222 | Heller et al. | Sep 1997 | A |
5685844 | Marttila | Nov 1997 | A |
5687734 | Dempsey et al. | Nov 1997 | A |
5704366 | Tacklind et al. | Jan 1998 | A |
5750926 | Schulman et al. | May 1998 | A |
5754111 | Garcia | May 1998 | A |
5764159 | Neftel | Jun 1998 | A |
5772635 | Dastur et al. | Jun 1998 | A |
5779665 | Mastrototaro et al. | Jul 1998 | A |
5788669 | Peterson | Aug 1998 | A |
5791344 | Schulman et al. | Aug 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5807336 | Russo et al. | Sep 1998 | A |
5814015 | Gargano et al. | Sep 1998 | A |
5822715 | Worthington et al. | Oct 1998 | A |
5832448 | Brown | Nov 1998 | A |
5840020 | Heinonen et al. | Nov 1998 | A |
5861018 | Feierbach et al. | Jan 1999 | A |
5868669 | Iliff | Feb 1999 | A |
5871465 | Vasko | Feb 1999 | A |
5879163 | Brown et al. | Mar 1999 | A |
5885245 | Lynch et al. | Mar 1999 | A |
5897493 | Brown | Apr 1999 | A |
5899855 | Brown | May 1999 | A |
5904708 | Goedeke | May 1999 | A |
5913310 | Brown | Jun 1999 | A |
5917346 | Gord | Jun 1999 | A |
5918603 | Brown | Jul 1999 | A |
5925021 | Castellano et al. | Jul 1999 | A |
5933136 | Brown | Aug 1999 | A |
5935099 | Peterson et al. | Aug 1999 | A |
5940801 | Brown | Aug 1999 | A |
5956501 | Brown | Sep 1999 | A |
5960403 | Brown | Sep 1999 | A |
5965380 | Heller et al. | Oct 1999 | A |
5972199 | Heller et al. | Oct 1999 | A |
5978236 | Faberman et al. | Nov 1999 | A |
5997476 | Brown | Dec 1999 | A |
5999848 | Gord et al. | Dec 1999 | A |
5999849 | Gord et al. | Dec 1999 | A |
6009339 | Bentsen et al. | Dec 1999 | A |
6032119 | Brown et al. | Feb 2000 | A |
6043437 | Schulman et al. | Mar 2000 | A |
6056718 | Funderburk | May 2000 | A |
6081736 | Colvin et al. | Jun 2000 | A |
6083710 | Heller et al. | Jul 2000 | A |
6088608 | Schulman et al. | Jul 2000 | A |
6101478 | Brown | Aug 2000 | A |
6103033 | Say et al. | Aug 2000 | A |
6119028 | Schulman et al. | Sep 2000 | A |
6120676 | Heller et al. | Sep 2000 | A |
6121009 | Heller et al. | Sep 2000 | A |
6134461 | Say et al. | Oct 2000 | A |
6143164 | Heller et al. | Nov 2000 | A |
6162611 | Heller et al. | Dec 2000 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6183412 | Benkowski et al. | Feb 2001 | B1 |
6246992 | Brown | Jun 2001 | B1 |
6259937 | Schulman et al. | Jul 2001 | B1 |
6329161 | Heller et al. | Dec 2001 | B1 |
6408330 | DeLaHuerga | Jun 2002 | B1 |
6424847 | Mastrototaro et al. | Jul 2002 | B1 |
6472122 | Schulman et al. | Oct 2002 | B1 |
6484045 | Holker et al. | Nov 2002 | B1 |
6484046 | Say et al. | Nov 2002 | B1 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6503381 | Gotoh et al. | Jan 2003 | B1 |
6514718 | Heller et al. | Feb 2003 | B2 |
6544173 | West et al. | Apr 2003 | B2 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6558320 | Causey, III et al. | May 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6560741 | Gerety et al. | May 2003 | B1 |
6565509 | Say et al. | May 2003 | B1 |
6579690 | Bonnecaze et al. | Jun 2003 | B1 |
6591125 | Buse et al. | Jul 2003 | B1 |
6592745 | Feldman et al. | Jul 2003 | B1 |
6605200 | Mao et al. | Aug 2003 | B1 |
6605201 | Mao et al. | Aug 2003 | B1 |
6607658 | Heller et al. | Aug 2003 | B1 |
6616819 | Liamos et al. | Sep 2003 | B1 |
6618934 | Feldman et al. | Sep 2003 | B1 |
6623501 | Heller et al. | Sep 2003 | B2 |
6641533 | Causey, III et al. | Nov 2003 | B2 |
6654625 | Say et al. | Nov 2003 | B1 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6671554 | Gibson et al. | Dec 2003 | B2 |
6676816 | Mao et al. | Jan 2004 | B2 |
6689265 | Heller et al. | Feb 2004 | B2 |
6728576 | Thompson et al. | Apr 2004 | B2 |
6733471 | Ericson et al. | May 2004 | B1 |
6746582 | Heller et al. | Jun 2004 | B2 |
6747556 | Medema et al. | Jun 2004 | B2 |
6749740 | Liamos et al. | Jun 2004 | B2 |
6752787 | Causey, III et al. | Jun 2004 | B1 |
6809653 | Mann et al. | Oct 2004 | B1 |
6881551 | Heller et al. | Apr 2005 | B2 |
6892085 | McIvor et al. | May 2005 | B2 |
6893545 | Gotoh et al. | May 2005 | B2 |
6895263 | Shin et al. | May 2005 | B2 |
6916159 | Rush et al. | Jul 2005 | B2 |
6932584 | Gray et al. | Aug 2005 | B2 |
6932894 | Mao et al. | Aug 2005 | B2 |
6942518 | Liamos et al. | Sep 2005 | B2 |
7153263 | Carter et al. | Dec 2006 | B2 |
7153289 | Vasko | Dec 2006 | B2 |
7396330 | Banet et al. | Jul 2008 | B2 |
7621893 | Moberg et al. | Nov 2009 | B2 |
7828764 | Moberg et al. | Nov 2010 | B2 |
7905868 | Moberg et al. | Mar 2011 | B2 |
20010044731 | Coffman et al. | Nov 2001 | A1 |
20020013518 | West et al. | Jan 2002 | A1 |
20020055857 | Mault et al. | May 2002 | A1 |
20020082665 | Haller et al. | Jun 2002 | A1 |
20020137997 | Mastrototaro et al. | Sep 2002 | A1 |
20020161288 | Shin et al. | Oct 2002 | A1 |
20030060765 | Campbell et al. | Mar 2003 | A1 |
20030078560 | Miller et al. | Apr 2003 | A1 |
20030088166 | Say et al. | May 2003 | A1 |
20030144581 | Conn et al. | Jul 2003 | A1 |
20030152823 | Heller | Aug 2003 | A1 |
20030176183 | Drucker et al. | Sep 2003 | A1 |
20030188427 | Say et al. | Oct 2003 | A1 |
20030199744 | Buse et al. | Oct 2003 | A1 |
20030208113 | Mault et al. | Nov 2003 | A1 |
20030220552 | Reghabi et al. | Nov 2003 | A1 |
20040061232 | Shah et al. | Apr 2004 | A1 |
20040061234 | Shah et al. | Apr 2004 | A1 |
20040064133 | Miller et al. | Apr 2004 | A1 |
20040064156 | Shah et al. | Apr 2004 | A1 |
20040073095 | Causey, III et al. | Apr 2004 | A1 |
20040074785 | Holker et al. | Apr 2004 | A1 |
20040093167 | Braig et al. | May 2004 | A1 |
20040097796 | Berman et al. | May 2004 | A1 |
20040102683 | Khanuja et al. | May 2004 | A1 |
20040111017 | Say et al. | Jun 2004 | A1 |
20040122353 | Shahmirian et al. | Jun 2004 | A1 |
20040167465 | Mihai et al. | Aug 2004 | A1 |
20040263354 | Mann et al. | Dec 2004 | A1 |
20050038331 | Silaski et al. | Feb 2005 | A1 |
20050038680 | McMahon | Feb 2005 | A1 |
20050154271 | Rasdal et al. | Jul 2005 | A1 |
20050192557 | Brauker et al. | Sep 2005 | A1 |
20060229694 | Schulman et al. | Oct 2006 | A1 |
20060238333 | Welch et al. | Oct 2006 | A1 |
20060293571 | Bao et al. | Dec 2006 | A1 |
20070088521 | Shmueli et al. | Apr 2007 | A1 |
20070135866 | Baker et al. | Jun 2007 | A1 |
20080154503 | Wittenber et al. | Jun 2008 | A1 |
20090081951 | Erdmann et al. | Mar 2009 | A1 |
20090082635 | Baldus et al. | Mar 2009 | A1 |
20090299299 | Lynch et al. | Dec 2009 | A1 |
20140350485 | Sonderegger | Nov 2014 | A1 |
Number | Date | Country |
---|---|---|
4329229 | Mar 1995 | DE |
0319268 | Nov 1988 | EP |
0806738 | Nov 1997 | EP |
0880936 | Dec 1998 | EP |
1338295 | Aug 2003 | EP |
1631036 | Mar 2006 | EP |
2218831 | Nov 1989 | GB |
WO 9620745 | Jul 1996 | WO |
WO 9636389 | Nov 1996 | WO |
WO 9637246 | Nov 1996 | WO |
WO 9721456 | Jun 1997 | WO |
WO 9820439 | May 1998 | WO |
WO 9824358 | Jun 1998 | WO |
WO 9842407 | Oct 1998 | WO |
WO 9849659 | Nov 1998 | WO |
WO 9859487 | Dec 1998 | WO |
WO 9908183 | Feb 1999 | WO |
WO 9910801 | Mar 1999 | WO |
WO 9918532 | Apr 1999 | WO |
WO 9922236 | May 1999 | WO |
WO 0010628 | Mar 2000 | WO |
WO 0019887 | Apr 2000 | WO |
WO 0048112 | Aug 2000 | WO |
WO 02058537 | Aug 2002 | WO |
WO 03001329 | Jan 2003 | WO |
WO 03094090 | Nov 2003 | WO |
WO 2005065538 | Jul 2005 | WO |
WO2009102355 | Aug 2009 | WO |
Entry |
---|
PCT Search Report (PCT/US02/03299), Oct. 31, 2002, Medtronic Minimed, Inc. |
(Animas Corporation, 1999). Animas . . . bringing new life to insulin therapy. |
Bode B W, et al. (1996). Reduction in Severe Hypoglycemia with Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes. Diabetes Care, vol. 19, No. 4, 324-327. |
Boland E (1998). Teens Pumping it Up! Insulin Pump Therapy Guide for Adolescents. 2nd Edition. |
Brackenridge B P (1992). Carbohydrate Gram Counting a Key to Accurate Mealtime Boluses in Intensive Diabetes Therapy. Practical Diabetology, vol. 11, No. 2, pp. 22-28. |
Brackenridge, B P et al. (1995). Counting Carbohydrates How to Zero in on Good Control. MiniMed Technologies Inc. |
Farkas-Hirsch R et al. (1994). Continuous Subcutaneous Insulin Infusion: A Review of the Past and Its Implementation for the Future. Diabetes Spectrum From Research to Practice, vol. 7, No. 2, pp. 80-84, 136-138. |
Hirsch I B et al. (1990). Intensive Insulin Therapy for Treatment of Type I Diabetes. Diabetes Care, vol. 13, No. 12, pp. 1265-1283. |
Kulkarni K et al. (1999). Carbohydrate Counting a Primer for Insulin Pump Users to Zero in on Good Control. MiniMed Inc. |
Marcus A O et al. (1996). Insulin Pump Therapy Acceptable Alternative to Injection Therapy. Postgraduate Medicine, vol. 99, No. 3, pp. 125-142. |
Reed J et al. (1996). Voice of the Diabetic, vol. 11, No. 3, pp. 1-38. |
Skyler J S (1989). Continuous Subcutaneous Insulin Infusion [CSII] With External Devices: Current Status. Update in Drug Delivery Systems, Chapter 13, pp. 163-183. Futura Publishing Company. |
Skyler J S et al. (1995). The Insulin Pump Therapy Book Insights from the Experts. MiniMed•Technologies. |
Strowig S M (1993). Initiation and Management of Insulin Pump Therapy. The Diabetes Educator, vol. 19, No. 1, pp. 50-60. |
Walsh J, et al. (1989). Pumping Insulin: The Art of Using an Insulin Pump. Published by MiniMed•Technologies. |
(Intensive Diabetes Management, 1995). Insulin Infusion Pump Therapy. pp. 66-78. |
(MiniMed, 1996). The MiniMed 506. 7 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054527/www.minimed.com/files/506—pic.htm. |
(MiniMed, 1997). MiniMed 507 Specifications. 2 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234841/www.minimed.com/files/mmn075.htm. |
(MiniMed, 1996). FAQ: The Practical Things . . . pp. 1-4. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054546/www.minimed.com/files/faq—pract.htm. |
(MiniMed, 1997). Wanted: a Few Good Belt Clips! 1 page. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234559/www.minimed.com/files/mmn002.htm. |
(MiniMed Technologies, 1994). MiniMed 506 Insulin Pump User's Guide. |
(MiniMed Technologies, 1994). MiniMed™ Dosage Calculator Initial Meal Bolus Guidelines / MiniMed™ Dosage Calculator Initial Basal Rate Guidelines Percentage Method. 4 pages. |
(MiniMed, 1996). MiniMed™ 507 Insulin Pump User's Guide. |
(MiniMed, 1997). MiniMed™ 507 Insulin Pump User's Guide. |
(MiniMed, 1998). MiniMed 507C Insulin Pump User's Guide. |
(MiniMed International, 1998). MiniMed 507C Insulin Pump for those who appreciate the difference. |
(MiniMed Inc., 1999). MiniMed 508 Flipchart Guide to Insulin Pump Therapy. |
(MiniMed Inc., 1999). Insulin Pump Comparison / Pump Therapy Will Change Your Life. |
(MiniMed, 2000). MiniMed® 508 User's Guide. |
(MiniMed Inc., 2000). MiniMed® Now [I] Can Meal Bolus Calculator / MiniMed® Now [I] Can Correction Bolus Calculator. |
(MiniMed Inc., 2000). Now [I] Can MiniMed Pump Therapy. |
(MiniMed Inc., 2000). Now [I] Can MiniMed Diabetes Management. |
(Medtronic MiniMed, 2002). The 508 Insulin Pump A Tradition of Excellence. |
(Medtronic MiniMed, 2002). Medtronic MiniMed Meal Bolus Calculator and Correction Bolus Calculator. International Version. |
Abel, P., et al., “Experience with an implantable glucose sensor as a prerequiste of an artificial beta cell,” Biomed. Biochim. Acta 43 (1984) 5, pp. 577-584. |
Bindra, Dilbir S., et al., “Design and in Vitro Studies of a Needle-Type Glucose Sensor for a Subcutaneous Monitoring,” American Chemistry Society, 1991, 63, pp. 1692-1696. |
Boguslavsky, Leonid, et al., “Applications of redox polymers in biosensors,” Sold State Ionics 60, 1993, pp. 189-197. |
Geise, Robert J., et al., “Electropolymerized 1,3-diaminobenzene for the construction of a 1,1′-dimethylferrocene mediated glucose biosensor,” Analytica Chimica Acta, 281, 1993, pp. 467-473. |
Gernet, S., et al., “A Planar Glucose Enzyme Electrode,” Sensors and Actuators, 17, 1989, pp. 537-540. |
Gernet, S., et al., “Fabrication and Characterization of a Planar Electromechanical Cell and its Application as a Glucose Sensor,” Sensors and Actuators, 18, 1989, pp. 59-70. |
Gorton, L., et al., “Amperometric Biosensors Based on an Apparent Direct Electron Transfer Between Electrodes and Immobilized Peroxiases,” Analyst, Aug. 1991, vol. 117, pp. 1235-1241. |
Gorton, L., et al., “Amperometric Glucose Sensors Based on Immobilized Glucose-Oxidizing Enymes and Chemically Modified Electrodes,” Analytica Chimica Acta, 249, 1991, pp. 43-54. |
Gough, D. A., et al., “Two-Dimensional Enzyme Electrode Sensor for Glucose,” Analytical Chemistry, vol. 57, No. 5, 1985, pp. 2351-2357. |
Gregg, Brian A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications,” Analytical Chemistry, pp. 258-263, 1990. |
Gregg, Brian A., et al., “Redox Polymer Films Containing Enzymes. 1. A Redox-Conducting Epoxy Cement: Synthesis, Characterization, and Electrocatalytic Oxidation of Hydroquinone,” The Journal of Physical Chemistry, vol. 95, No. 15, 1991, pp. 5970-5975. |
Hashiguchi, Yasuhiro, MD, et al., “Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor With Microdialysis Sampling Method,” Diabetes Care, vol. 17, No. 5, May 1994, pp. 387-389. |
Heller, Adam, “Electrical Wiring of Redox Enzymes,” Acc. Chem. Res., vol. 23, No. 5, May 1990, pp. 128-134. |
Jobst, Gerhard, et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring,” Analytical Chemistry, vol. 68, No. 18, Sep. 15, 1996, pp. 3173-3179. |
Johnson, K.W., et al., “In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue,” Biosensors & Bioelectronics, 7, 1992, pp. 709-714. |
Jönsson, G., et al., “An Electromechanical Sensor for Hydrogen Peroxide Based on Peroxidase Adsorbed on a Spectrographic Graphite Electrode,” Electroanalysis, 1989, pp. 465-468. |
Kanapieniene, J. J., et al., “Miniature Glucose Biosensor with Extended Linearity,” Sensors and Actuators, B. 10, 1992, pp. 37-40. |
Kawamori, Ryuzo, et al., “Perfect Normalization of Excessive Glucagon Responses to Intraveneous Arginine in Human Diabetes Mellitus With the Artificial Beta-Cell,” Diabetes vol. 29, Sep. 1980, pp. 762-765. |
Kimura, J., et al., “An Immobilized Enzyme Membrane Fabrication Method,” Biosensors 4, 1988, pp. 41-52. |
Koudelka, M., et al., “In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors,” Biosensors & Bioelectronics 6, 1991, pp. 31-36. |
Koudelka, M., et al., “Planar Amperometric Enzyme-Based Glucose Microelectrode,” Sensors & Actuators, 18, 1989, pp. 157-165. |
Mastrototaro, John J., et al., “An electroenzymatic glucose sensor fabricated on a flexible substrate,” Sensors & Actuators, B. 5, 1991, pp. 139-144. |
Mastrototaro, John J., et al., “An Electroenzymatic Sensor Capable of 72 Hour Continuous Monitoring of Subcutaneous Glucose,” 14th Annual International Diabetes Federation Congress, Washington D.C., Jun. 23-28, 1991. |
McKean, Brian D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors,” IEEE Transactions on Biomedical Engineering, Vo. 35, No. 7, Jul. 1988, pp. 526-532. |
Monroe, D., “Novel Implantable Glucose Sensors,” ACL, Dec. 1989, pp. 8-16. |
Morff, Robert J., et al., “Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors,” Annuaal International Conference of teh IEEE Engineering in Medicine and Biology Society, Vo. 12, No. 2, 1990, pp. 483-484. |
Moussy, Francis, et al., “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating,” Analytical Chemistry, vol. 65, No. 15, Aug. 1, 1993, pp. 2072-2077. |
Nakamoto, S., et al., “A Lift-Off Method for Patterning Enzyme-Immobilized Membranes in Multi-Biosensors,” Sensors and Actuators 13, 1988, pp. 165-172. |
Nishida, Kenro, et al., “Clinical applications of teh wearable artifical endocrine pancreas with the newly designed needle-type glucose sensor,” Elsevier Sciences B.V., 1994, pp. 353-358. |
Nishida, Kenro, et al., “Development of a ferrocene-mediated needle-type glucose sensor covereed with newly designd biocompatible membrane, 2-methacryloyloxyethylphosphorylcholine-co-n-butyl nethacrylate,” Medical Progress Through Technology, vol. 21, 1995, pp. 91-103. |
Poitout, V., et al., “A glucose monitoring system for on line estimation oin man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue adn a wearable control unit,” Diabetologia, vol. 36, 1991, pp. 658-663. |
Reach, G., “A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors,” Biosensors 2, 1986, pp. 211-220. |
Shaw, G. W., et al., “In vitro testing of a simply constructed, highly stable glucose sensor suitable for implantation in diabetic patients,” Biosensors & Bioelectronics 6, 1991, pp. 401-406. |
Shichiri, M., “A Needle-Type Glucose Sensor—A Valuable Tool Not Only for a Self-Blood Glucose Monitoring but for a Wearable Artifiical Pancreas,” Life Support Systems Proceedings, XI Annual Meeting ESAO, Alpbach-Innsbruck, Austria, Sep. 1984, pp. 7-9. |
Shichiri, Motoaki, et al., “An artificial endocrine pancreas—problems awaiting solution for long-term clinical applications of a glucose sensor,” Frontiers Med. Biol. Engng., 1991, vol. 3, No. 4, pp. 283-292. |
Shichiri, Motoaki, et al., “Closed-Loop Glycemic Control with a Wearable Artificial Endocrine Pancreas—Variations in Daily Insulin Requirements to Glycemic Response,” Diabetes, vol. 33, Dec. 1984, pp. 1200-1202. |
Shichiri, Motoaki, et al., “Glycaemic Control in a Pacreatectomized Dogs with a Wearable Artificial Endocrine Pancreas,” Diabetologia, vol. 24, 1983, pp. 179-184. |
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers,” Hormone and Metabolic Research, Supplement Series vol. No. 20, 1988, pp. 17-20. |
Shichiri, M., et al., “Membrane design for extending the long-life of an implantable glucose sensor,” Diab. Nutr. Metab., vol. 2, No. 4, 1989, pp. 309-313. |
Shichiri, Motoaki, et al., “Normalization of the Paradoxic Secretion of Glucagon in Diabetes Who Were Controlled by the Artificial Beta Cell,” Diabetes, vol. 28, Apr. 1979, pp. 272-275. |
Shichiri, Motoaki, et al., “Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A useful Tool for Blood Glucose Monitoring in Diabetic Individuals,” Diabetes Care, vol. 9, No. 3, May-Jun. 1986, pp. 298-301. |
Shichiri, Motoaki, et al., “Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor,” The Lancet, Nov. 20, 1982, pp. 1129-1131. |
Shichiri, Motoaki, et al., “The Wearable Artificial Endocrine Pancreas with a Needle-Type Glucose Sensor: Perfect Glycemic Control in Ambulatory Diabetes,” Acta Paediatr Jpn 1984, vol. 26, pp. 359-370. |
Shinkai, Seiji, “Molecular Recognitiion of Mono- and Di-saccharides by Phenylboronic Acids in Solvent Extraction and as a Monolayer,” J. Chem. Soc., Chem. Commun., 1991, pp. 1039-1041. |
Shults, Mark C., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors,” IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, Oct. 1994, pp. 937-942. |
Sternberg, Robert, et al., “Study and Development of Multilayer Needle-type Enzyme-based Glucose Microsensors,” Biosensors, vol. 4, 1988, pp. 27-40. |
Tamiya, E., et al., “Micro Glucose Sensors using Electron Mediators Immobilized on a Polypyrrole-Modified Electrode,” Sensors and Actuators, vol. 18, 1989, pp. 297-307. |
Tsukagoshi, Kazuhiko, et al., “Specific Complexation with Mono- and Disaccharides that can be Detected by Circular Dichroism,” J. Org. Chem., vol. 56, 1991, pp. 4089-4091. |
Urban, G., et al., “Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applciations,” Biosensors & Bioelectronics, vol. 7, 1992, pp. 733-739. |
Ubran, G., et al., “Miniaturized thin-film biosensors using covalently immobilized glucose oxidase,” Biosensors & Bioelectronics, vol. 6, 1991, pp. 555-562. |
Velho, G., et al., “In vivo calibration of a subcutaneous glucose sensor for determination of subcutaneous glucose kinetics,” Diab. Nutr. Metab., vol. 3, 1988, pp. 227-233. |
Wang, Joseph, et al., “Needle-Type Dual Microsensor for the Simultaneous Monitoring of Glucose and Insulin,” Analytical Chemistry, vol. 73, 2001, pp. 844-847. |
Yamasaki, Yoshimitsu, et al., “Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor,” Clinics Chimica Acta, vol. 93, 1989, pp. 93-98. |
Yokoyama, K., “Integrated Biosensor for Glucose and Galactose,” Analytica Chimica Acta, vol. 218, 1989, pp. 137-142. |
Number | Date | Country | |
---|---|---|---|
20130184541 A1 | Jul 2013 | US |
Number | Date | Country | |
---|---|---|---|
61586647 | Jan 2012 | US |